Name: IL1RAP (Nadunolimab Biosimilar) Recombinant Monoclonal Antibody
Brand: CUSABIO
SKU: CSB-RA878844MB5HU

Product Details

Uniprot No.

Q9NPH3

Target Names

IL1RAP

Alternative Names

CAN04 research-grade biosimilar; CAN-04 research-grade biosimilar; Nidanilimab research-grade biosimilar ;IL1RAP antibody; C3orf13 antibody; IL1R3 antibody; Interleukin-1 receptor accessory protein antibody; IL-1 receptor accessory protein antibody; IL-1RAcP antibody; EC 3.2.2.6 antibody; Interleukin-1 receptor 3 antibody; IL-1R-3 antibody; IL-1R3 antibody

Species Reactivity

Human

Immunogen

Recombinant Human IL1RAP protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

0.01M PBS，pH7.4

Form

Liquid

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

3-4 weeks

Description

This recombinant monoclonal antibody is a research-grade biosimilar to Nadunolimab, targeting IL-1 receptor accessory protein (IL1RAP). IL1RAP functions as an essential co-receptor in interleukin-1 and interleukin-33 signaling pathways, playing a critical role in inflammatory responses and immune regulation. This protein is aberrantly expressed in various malignancies, including acute myeloid leukemia, multiple myeloma, and solid tumors, where it contributes to cancer stem cell maintenance, tumor progression, and immune evasion. Elevated IL1RAP expression has been associated with poor prognosis and treatment resistance across multiple cancer types.

Nadunolimab (CAN04) is a humanized IgG1 monoclonal antibody currently under clinical investigation for treating solid tumors and hematological malignancies. By blocking IL1RAP, it inhibits tumor-promoting inflammatory signaling while potentially enhancing antibody-dependent cellular cytotoxicity against cancer cells. This biosimilar provides researchers with a valuable tool for investigating IL1RAP-mediated pathways in oncology, inflammation, and immunology studies, as well as for exploring therapeutic mechanisms relevant to IL-1 family cytokine signaling.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Target Background

Function

Coreceptor for IL1RL2 in the IL-36 signaling system. Coreceptor with IL1R1 in the IL-1 signaling system. Associates with IL1R1 bound to IL1B to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Recruits TOLLIP to the signaling complex. Does not bind to interleukin-1 alone; binding of IL1RN to IL1R1, prevents its association with IL1R1 to form a signaling complex. The cellular response is modulated through a non-signaling association with the membrane IL1R2 decoy receptor. Coreceptor for IL1RL1 in the IL-33 signaling system. Can bidirectionally induce pre- and postsynaptic differentiation of neurons by trans-synaptically binding to PTPRD. May play a role in IL1B-mediated costimulation of IFNG production from T-helper 1 (Th1) cells (Probable).; Associates with secreted ligand-bound IL1R2 and increases the affinity of secreted IL1R2 for IL1B; this complex formation may be the dominant mechanism for neutralization of IL1B by secreted/soluble receptors. Enhances the ability of secreted IL1R1 to inhibit IL-33 signaling.; Unable to mediate canonical IL-1 signaling. Required for Src phosphorylation by IL1B. May be involved in IL1B-potentiated NMDA-induced calcium influx in neurons.

Gene References into Functions

Expression level of sIL1RAP may become one of the potential indexes for determining the prognosis of low-grade gliomas PMID: 29238884
These results provide novel insights into the role of IL1RAP in CML and a strong rationale for the development of an IL1RAP antibody therapy to target residual CML stem cells. PMID: 27621309
single nucleotide polymorphism A471T in the Toll-interleukin 1 receptor domain (TIR) of the IL-1Rrp2 that is present in approximately 2% of the human population, down-regulated IL-36R signaling by a decrease of interaction with IL-1RAcP. PMID: 27307043
The findings of this study support IL1RAP as a novel potential Alzheimer's disease target and highlight the use of amyloid PET as a valuable Alzheimer's disease endophenotype, particularly in a longitudinal framework. PMID: 26268530
The SNP rs4624606 in IL-1RAcP was nominally associated with CAD risk. PMID: 25517029
Data suggest serum levels of soluble IL1RAP (from alternative splicing) are down-regulated in endometriosis throughout menstrual cycle; IL1RAP levels (which peak in proliferative phase in fertile women) exhibit minor variations in endometriosis. PMID: 24935223
Plasma sIL1RAP levels are reduced in obesity and can potentially act as biomarkers of obesity. PMID: 24915116
Combined crystallography and small-angle X-ray-scattering studies reveal that ST2 possesses hinge flexibility between the D3 domain and D1D2 module, whereas IL-1RAcP exhibits a rigid conformation in the unbound state in solution. PMID: 23980170
Knockdown of IL1RAP decreased clonogenicity and increased cell death of AML cells. PMID: 22723552
Interleukin-1R3 mediates interleukin-1-induced potassium current increase through fast activation of Akt kinase. PMID: 22778412
decreased protein levels in the peritoneal fluid of women with endometriosis PMID: 21958553
Studies indicate that new targets have recently been investigated as potential modulators in myeloid leukemia pathogenesis, including miR-328, BMI1, FOXOs and IL1RAP. PMID: 21373837
This study showed a significant downregulation of soluble interleukin-1 receptor accessory protein expression in the endometrium of women with endometriosis. PMID: 21272866
identifies IL1RAP as a unique cell surface biomarker distinguishing Ph(+) from Ph(-) candidate chronic myeloid leukemia (CML) stem cells and opens up a previously unexplored avenue for therapy of CML PMID: 20805474
Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling PMID: 11880380
soluble form of IL-1R AcP contributes to the antagonism of IL-1 action by the type II decoy receptor PMID: 12530978
The dramatic changes in levels of IL-1RAcP mRNAs suggest important functions in regulating sensitivity to IL-1 during stress and may play a role in oncogenic processes that are engaged during chronic inflammation. PMID: 12781872
IL-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP in Jurkat cells PMID: 14734551
Specific destabilization of membrane-bound IL-1 receptor accessory protein mRNA in HepG2 hepatoma cells is mediated by its 2.8-kilobase 3'-untranslated region. PMID: 15528363
Analysis of a three-dimensional docking model of the TIR-TIR interaction between MyD88 and IL1RAcP PMID: 15849357
IL-1ra is associated with preserved beta-cell capacity in type 1 diabetes. PMID: 18299313
an isoform of the IL-1 receptor accessory protein (termed AcPb) was identified that is expressed exclusively in the CNS. PMID: 19481478

Hide All

Subcellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.; [Isoform 3]: Secreted.

Protein Families

Interleukin-1 receptor family

Tissue Specificity

Detected in liver, skin, placenta, thymus and lung. Isoform 4 is predominantly expressed in brain. Overexpressed on candidate chronic myeloid leukemia (CML) stem cells, hematopoietic stem cells and mononuclear cells of patients with acute myeloid leukemia

Database Links

HGNC: 5995

OMIM: 602626

KEGG: hsa:3556

UniGene: Hs.478673

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA878844MB5HU
Size	US$9799
	Order now
Have Questions?	Leave a Message or Start an on-line Chat

IL1RAP (Nadunolimab Biosimilar) Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background